0104 CBC R-Bridge
BioCentury & Getty Images

Finance

With first royalty deal done, CBC’s R-Bridge fund aims for Asia-focused biotechs’ non-dilutive sweet spots

Debut deal for $300M fund brings in royalty streams for Paratek’s Nuzyra

The debut deal for CBC’s new $300 million fund brings in royalty streams for Paratek’s anti-infective drug Nuzyra.

Jan 4, 2021 | 10:12 PM GMT

CBC Group believes the maturing market for innovative products in Greater China represents an opportunity sufficient to support its launch

Read the full 758 word article

How to gain access

Continue reading with a
two-week free trial.